VCAM1 and colitis: Sans et al [121] first demonstrated the diagnostic capability of anti-VCAM-1 mAbs for assessing colonic inflammatory damage by performing scintigraphic and biodistribution studies of intravenously administered iodine-123 (123I)-labelled 5F10 probes in rat models of TNBS-induced colitis.